CorMatrix Cardiovascular (Marietta, Georgia) reported that the FDA has granted the company full IDE approval for its ongoing multi-center, prospective, randomized clinical trial aiming to demonstrate the safety and efficacy of the CorMatrix ECM for pericardial closure to reduce the incidence of new onset postoperative atrial fibrillation following isolated primary coronary artery bypass graft (CABG) surgery.